Quarterly report pursuant to Section 13 or 15(d)

Basis of Presentation and Summary of Significant Accounting Policies - Revenue by Source (Details)

v3.22.2.2
Basis of Presentation and Summary of Significant Accounting Policies - Revenue by Source (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Disaggregation of Revenue [Line Items]        
Total revenue $ 66,088 $ 64,835 $ 169,200 $ 204,660
Royalties        
Disaggregation of Revenue [Line Items]        
Total revenue 19,837 15,648 51,491 31,376
Kyprolis        
Disaggregation of Revenue [Line Items]        
Total revenue 9,123 8,821 20,872 18,548
Evomela        
Disaggregation of Revenue [Line Items]        
Total revenue 3,123 2,665 8,218 7,191
Teriparatide injection        
Disaggregation of Revenue [Line Items]        
Total revenue 4,071 2,567 12,484 2,831
Rylaze        
Disaggregation of Revenue [Line Items]        
Total revenue 2,099 600 6,065 600
Other        
Disaggregation of Revenue [Line Items]        
Total revenue 1,421 995 3,852 2,206
Captisol        
Disaggregation of Revenue [Line Items]        
Total revenue 35,949 35,093 77,616 128,875
Captisol - Core        
Disaggregation of Revenue [Line Items]        
Total revenue 3,582 5,374 13,133 16,310
Captisol - COVID        
Disaggregation of Revenue [Line Items]        
Total revenue 32,367 29,719 64,483 112,565
Contract revenue        
Disaggregation of Revenue [Line Items]        
Total revenue 10,302 14,094 40,093 44,409
Service Revenue        
Disaggregation of Revenue [Line Items]        
Total revenue 4,975 4,828 15,574 17,650
License Fees        
Disaggregation of Revenue [Line Items]        
Total revenue 460 200 5,154 2,293
Milestone        
Disaggregation of Revenue [Line Items]        
Total revenue 3,658 7,419 14,022 19,436
Other        
Disaggregation of Revenue [Line Items]        
Total revenue $ 1,209 $ 1,647 $ 5,343 $ 5,030